After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
CGEM belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Cullinan Therapeutics Inc is $642.16M. A total of 0.55 million shares were traded on the day, compared to an average of 1.07M shares.
In the most recent transaction, AHMED NADIM sold 9,922 shares of CGEM for 10.01 per share on Dec 23 ’25. After the transaction, the President and CEO now owns 420,699 company shares. In a previous transaction on Dec 19 ’25, Michaelson Jennifer sold 1,345 shares at 10.01 per share. CGEM shares that Chief Scientific Officer owns now total 132,635.
Among the insiders who sold shares, SUMER JACQUELYN L disposed of 3,480 shares on Dec 18 ’25 at a per-share price of $9.67. This resulted in the Chief Legal Officer holding 135,432 shares of CGEM after the transaction. In another insider transaction, Jones Jeffrey Alan sold 4,632 shares at $9.67 per share on Dec 18 ’25. Company shares held by the Chief Medical Officer now total 169,532.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, CGEM has a high of $13.33 and a low of $5.68.
As of this writing, CGEM has an earnings estimate of -$0.81 per share for the current quarter. EPS was calculated based on a consensus of 7.0 estimates, with a high estimate of -$0.49 per share and a lower estimate of -$0.99. The company reported an EPS of -$0.73 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. CGEM’s latest balance sheet shows that the firm has $290.47M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $11.75M in liabilities at the time. Its Book Value Per Share was $7.64, while its Total Shareholder’s Equity was $425.37M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock.
